News AnaptysBio, Inc.

Equities

ANAB

US0327241065

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
19.83 ^USD	-7.64%		-19.81%	-7.42%

Apr. 16	Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target	MT
Apr. 11	Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target	Apr. 16	MT
Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target	Apr. 11	MT
JPMorgan Adjusts Price Target on AnaptysBio to $28 From $30, Maintains Neutral Rating	Apr. 01	MT
AnaptysBio, Inc.(NasdaqGS:ANAB) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
AnaptysBio Shares Jump on Upgrade by Wedbush	Mar. 12	MT
Wedbush Upgrades AnaptysBio to Outperform From Neutral, Says Derivative, Clinical Catalysts to Drive Shares Higher; Raises PT to $34 From $20	Mar. 12	MT
AnaptysBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Mar. 11	GL
AnaptysBio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 11	CI
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting	Feb. 29	GL
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting	Feb. 29	AQ
BTIG Initiates Coverage on AnaptysBio With Buy Rating, $55 Price Target	Feb. 26	MT
AnaptysBio Shares Climb as Piper Sandler Starts Coverage With Overweight Rating	Feb. 16	MT
Piper Sandler Initiates AnaptysBio at Overweight Rating With $80 Price Target	Feb. 16	MT
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference	Jan. 31	GL
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference	Jan. 31	AQ
AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from S&P Biotechnology Select Industry Index	Dec. 18	CI
GSK: EU approves Jemperli for endometrial cancer	Dec. 11	CF
AnaptysBio Secures Exclusive License for Centessa's BDCA2 Modulator Antibody Portfolio	Nov. 27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News AnaptysBio, Inc.

Equities

ANAB

US0327241065

Summary

Filters